Baxter International is a healthcare company that focuses on developing and providing a wide range of medical products and services to enhance patient care. The company specializes in creating innovative therapies and solutions for various health conditions, including renal and hospital care. With a strong emphasis on sustainability and improving patient outcomes, Baxter manufactures essential medical devices, pharmaceuticals, and biotechnology products that support the treatment of chronic diseases and acute medical conditions. Their commitment to research and development drives advancements in healthcare technology, helping to meet the needs of healthcare professionals and patients worldwide. Read More
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Baxter International, Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, both dates inclusive (the “Class Period”), have until December 15, 2025 to seek appointment as lead plaintiff of the Baxter class action lawsuit. Captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., No. 25-cv-12672 (N.D. Ill.), the Baxter class action lawsuit charges Baxter and certain of Baxter’s top current and former executives with violations of the Securities Exchange Act of 1934.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Baxter (BAX) To Contact Him Directly To Discuss Their Options
SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Baxter International, Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025. Baxter is a global company that develops, manufactures, and markets medical products used in hospitals and other healthcare facilities.
The DJS Law Group reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Baxter International, Inc. (“Baxter” or the “Company”) (NYSE:BAX) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Baxter International Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, both dates inclusive (the “Class Period”). Baxter develops, manufactures, and markets medical products.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Labaton Keller Sucharow LLP (“Labaton”) has filed a securities class action lawsuit (the “Action”) on behalf of its client the Electrical Workers Pension Fund, Local 103, I.B.E.W. (“Local 103”) against Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) and certain of its executives (collectively, “Defendants”). The Action, which is captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., No. 25-cv-12672 (N.D. Ill.), asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder, on behalf of all persons and entities that purchased or otherwise acquired Baxter common stock between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”).
Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its third-quarter 2025 financial results on Thursday, October 30, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I156235 to pre-register for the call and receive the call information.
Shares of healthcare company Baxter International (NYSE:BAX)
fell 3% in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s 13.9% return has trailed the S&P 500 by 18.8 percentage points.
Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced that it has been awarded a Gold Level Resiliency Badge from the Healthcare Industry Resilience Collaborative (HIRC) in the categories of IV Solutions, Nutrition Solutions and Premix Drugs. Baxter is the first manufacturer to earn this distinction across these categories, underscoring Baxter’s commitment to building a stronger, more reliable supply chain.
The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—including PPE, consumables, and medical devices—to assess reliance on foreign suppliers for critical health products.
Shares of healthcare company Baxter International (NYSE:BAX)
fell 3.7% in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Baxter has gotten torched over the last six months - since March 2025, its stock price has dropped 32% to $22.86 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Baxter International Inc. (NYSE:BAX), a leading global medtech company, today launched the Welch Allyn Connex 360 Vital Signs Monitor, its next generation patient monitoring device. As the latest innovation in Baxter’s connected monitoring portfolio, Connex 360 offers an advanced connectivity and security platform, customizable configurations based on a hospital’s clinical routines, and upgrade capabilities that set the stage for future functionality and enhancements. With automated clinical documentation, Connex 360 is designed to simplify the clinician experience and allow more time to focus on patients.
